{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:00:32Z","timestamp":1777694432060,"version":"3.51.4"},"reference-count":133,"publisher":"Elsevier","isbn-type":[{"value":"9780443192869","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.acc.2022.12.001","type":"book-chapter","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T12:24:29Z","timestamp":1673871869000},"page":"273-315","source":"Crossref","is-referenced-by-count":3,"title":["Hemophilia A: Emicizumab monitoring and impact on coagulation testing"],"prefix":"10.1016","author":[{"given":"Michael A.","family":"Nardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.acc.2022.12.001_bb0010","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"334","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0015","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474086.2018.1531701","article-title":"Emicizumab for hemophilia A with factor VIII inhibitors","volume":"11","author":"Young","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1365-2516.2009.02074.x","article-title":"Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with hemophilia diagnosed before the age of 2 years: a report from the Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project","volume":"15","author":"Kulkarni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0025","article-title":"Circumcision in males with bleeding disorders","volume":"5","author":"Mansouritoghabeh","year":"2013","journal-title":"Hematol. Infect. Dis."},{"key":"10.1016\/bs.acc.2022.12.001_bb0030","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.14844","article-title":"Intracranial haemorrhage in children and adolescents with severe haemophilia A or B\u2014the impact of prophylactic treatments","volume":"179","author":"Andersson","year":"2017","journal-title":"Br. J. Haemotol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2006.01776.x","article-title":"Life expectancy in hemophilia outcome","volume":"4","author":"Mejia-Carvajal","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/hae.13361","article-title":"Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study","volume":"24","author":"Khair","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13641","article-title":"Emicizumab: review of the literature and critical appraisal","volume":"25","author":"Rodriguez-Merchan","year":"2019","journal-title":"Haemophilila"},{"issue":"Suppl. 2","key":"10.1016\/bs.acc.2022.12.001_bb0065","first-page":"16","article-title":"Real-world prospective data on bleeding frequency in 1,000 patients with hemophilia A\u2014Is the goal of zero bleeds achievable?","volume":"23","author":"Oldenburg","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0070","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/hae.12859","article-title":"Prophylaxis vs on-demand treatment with Nuwiq\u00ae (Human-cl rhFVIII) in adults with severe haemophilia A","volume":"22","author":"Tiede","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/bs.acc.2022.12.001_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/17474086.2015.1002465","article-title":"Individualizing prophylaxis in hemophilia: a review","volume":"8","author":"Petrini","year":"2015","journal-title":"Exp. Rev. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0090","first-page":"518","article-title":"Prophylaxis for hemophilia in the era of extended half-life factor FVIII\/factor IX products","volume":"16","author":"Berntorp","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0095","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0037-1612626","article-title":"Inhibitors in hemophilia: treatment challenges and novel options","volume":"44","author":"Barg","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 4","key":"10.1016\/bs.acc.2022.12.001_bb0100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2516.2004.00993.x","article-title":"Inhibitors in haemophilia: clinical aspects","volume":"10","author":"DiMichele","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-2007-1000659","article-title":"Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for Factor VIII","volume":"21","author":"Kreuz","year":"1995","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.12.001_bb0110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13145","article-title":"Inhibitor development in haemophilia","volume":"23","author":"Peyvandi","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0115","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus."},{"key":"10.1016\/bs.acc.2022.12.001_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hoc.2019.01.007","article-title":"Hemophilia in a changing treatment landscape","volume":"33","author":"Pelland-Marcotte","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/bs.acc.2022.12.001_bb0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2017.284356","article-title":"Advances in the treatment of hemophilia: implications for laboratory testing","volume":"65","author":"Tripodi","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2022.12.001_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","article-title":"Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity","volume":"111","author":"Kitazawa","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0135","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0140","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2022.12.001_bb0150","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-09-743385","article-title":"Novel therapeutics for hemophilia and other bleeding disorders","volume":"132","author":"Callaghan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14712598.2019.1626370","article-title":"Emicizumab for the prevention of bleeds in hemophilia A","volume":"19","author":"Mahlangu","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/bs.acc.2022.12.001_bb0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0175","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0180","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0185","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/bs.acc.2022.12.001_bb0190","unstructured":"ClinicalTrials.gov website, n.d. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=emicizumab&cntry=&state=&city=&dist=, (Accessed May 27, 2022)."},{"key":"10.1016\/bs.acc.2022.12.001_bb0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.acc.2018.10.003","article-title":"Emicizumab (ACE910): clinical background and laboratory assessment of hemophilia A","volume":"88","author":"Lippi","year":"2019","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2022.12.001_bb0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474086.2019.1624519","article-title":"Emicizumab for hemophilia without inhibitors","volume":"12","author":"Cafuir","year":"2019","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0205","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0215","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0220","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1016\/bs.acc.2022.12.001_bb0240","article-title":"Final Analysis of the STASEY trial: a single-arm, multicenter, open-label, phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A (PwHA) with factor (F)VIII inhibitors","volume":"5","author":"Jimenez-Yuste","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0245","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.acc.2022.12.001_bb0250","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cpdd.805","article-title":"Evaluation of the pharmacokinetics, pharmacodynamics, and safety of a single dose of emicizumab in healthy Chinese subjects","volume":"10","author":"Li","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.12.001_bb0255","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2021-146009","article-title":"Emicizumab prophylaxis in persons with mild and moderate hemophilia A: results from the interim analysis of the HAVEN 6 study","volume":"138","author":"Negier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0260","unstructured":"ClinicalTrials.gov website, n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431726?term=HAVEN+7&draw=2&rank=1, (Accessed May 27, 2022)."},{"key":"10.1016\/bs.acc.2022.12.001_bb0265","unstructured":"ClinicalTrials.gov website, n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04030052?cond=NCT04030052&draw=2&rank=1, (Accessed May 27, 2022)."},{"key":"10.1016\/bs.acc.2022.12.001_bb0270","unstructured":"ClinicalTrials.gov website, n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303559?term=NCT04303559&draw=2&rank=1, (Accessed May 27, 2022)."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.12.001_bb0275","first-page":"164","article-title":"Synergistic interplay of a sequence identical analog of ACE910, a bispecific antibody, and a bypassing reagent and its components","volume":"1","author":"Hartmann","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0280","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.V130.Suppl_1.90.90","article-title":"Elucidating the excessive pro-coagulant effect of a sequence identical analog to ACE910 in combination with bypassing agents","volume":"130","author":"Hartmann","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1055\/s-0040-1714279","article-title":"Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A","volume":"120","author":"Gelbenegger","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0295","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0300","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1046\/j.1538-7836.2003.00428.x","article-title":"Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface","volume":"1","author":"Ahmad","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 77","key":"10.1016\/bs.acc.2022.12.001_bb0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12500","article-title":"One-stage vs. chromogenic assays in haemophilia A","volume":"94","author":"Potgieter","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0310","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2516.2003.00773.x","article-title":"Standardization of FVIII and FIX assays","volume":"9","author":"Barrowcliffe","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1016\/bs.acc.2022.12.001_bb0315","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.13012","article-title":"Recombinant to modified factor VIII amd factor IX\u2014chromogenic and one-stage assays issues","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0037-1598058","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"Kitchen","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0325","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.23723","article-title":"Chromogenic factor VIII activity assay","volume":"89","author":"Moser","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0330","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0335","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1309\/AJCPMKP94CODILWS","article-title":"Laboratory assessment of factor VIII inhibitor titer: the North American specialized Coagulation Laboratory Association experience","volume":"131","author":"Peerschke","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0340","first-page":"293","article-title":"Laboratory identification of factor inhibitors: an update","volume":"44","author":"Kenshaw","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/bs.acc.2022.12.001_bb0345","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jth.12259","article-title":"Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study","volume":"11","author":"Miller","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0350","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0355","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"Muller","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0360","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1538-7836.2012.04705.x","article-title":"Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance","volume":"10","author":"Miller","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0365","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0370","first-page":"e204","article-title":"Measurement of antifactor VIII antibody titre in the presence of emicizumab: use of chromogenic Bethesda assay","volume":"42","author":"Bowyer","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0375","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/ijlh.13384","article-title":"Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia A patients receiving emicizumab","volume":"43","author":"Miller","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0380","first-page":"724","article-title":"Factor VIII inhibitor testing using a validated chromogenic Bethesda assay in HAVEN 1 (BH29884), a phase 3 trial of emicizumab in persons with haemophilia A with inhibitors","volume":"1","author":"Adamkewicz","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0385","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"Issue S5","key":"10.1016\/bs.acc.2022.12.001_bb0390","first-page":"46","article-title":"Agreement between a chromogenic modified Nijmegen-Bethesda assay and a qualitative ELISA test in detection of factor VIII inhibitors in plasma from persons with hemophilia A (PwHA)","volume":"24","author":"Sadeghi-Kohmami","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0395","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays for factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0400","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14177","article-title":"Effects of emicizumab on APTT, FVIII assays and FVIII inhibitor assays using different reagents: results of a UK NEQAS proficiency testing exercise","volume":"26","author":"Lowe","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0405","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11239-019-01993-9","article-title":"Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban and argatroban","volume":"49","author":"Tripodi","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/bs.acc.2022.12.001_bb0410","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0415","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0420","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0425","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/hae.13565","article-title":"Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients","volume":"245","author":"Rampersad","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0430","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/ijlh.13114","article-title":"Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays","volume":"42","author":"Adamkewicz","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0435","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"Tripodi","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2022.12.001_bb0440","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation","volume":"18","author":"Druzgal","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0445","first-page":"577","article-title":"Blutgerinnungsstudien mit der Thrombelastographie; einem neuen Untersuchungs verfahren","volume":"36","author":"Hartert","year":"1948","journal-title":"Lin Worchenschr."},{"key":"10.1016\/bs.acc.2022.12.001_bb0450","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.seminhematol.2015.10.001","article-title":"Global assays in hemophilia","volume":"53","author":"Chitlur","year":"2016","journal-title":"Semin. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0455","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/jcp.6.1.3","article-title":"A thrombin generation test; the application in haemophilia and thrombocytopenia","volume":"6","author":"Macfarlane","year":"1953","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0465","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/jth.15640","article-title":"Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review","volume":"20","author":"Verhagen","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0470","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/Xa bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0475","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jth.12458","article-title":"Recommendations for performing thromboelastography\/thromboelastometry in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Chitlur","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0480","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0485","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/jth.12287","article-title":"Towards standardization of clot waveform analysis and recommendations for its clinical applications","volume":"11","author":"Shima","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0490","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the haven clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0495","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0500","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1538-7836.2004.00528.x","article-title":"Whole blood clot formation phenotype in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa","volume":"2","author":"Sorensen","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0505","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2516.2006.01319.x","article-title":"Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelasttography","volume":"12","author":"Young","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0510","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1160\/TH10-01-0019","article-title":"Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor\u2014clinical outcome and laboratory observations","volume":"103","author":"Sorensen","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0515","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2516.2008.01877.x","article-title":"Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?","volume":"15","author":"Salvagno","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0520","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/hae.12110","article-title":"Monitoring rFVIII prophylaxis dosing using global haemostasis assays","volume":"19","author":"Al Hawaj","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0525","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2516.2008.01688.x","article-title":"Effects of factor VIII inhibitors bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma","volume":"14","author":"Livnat","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0530","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2516.2009.02028.x","article-title":"Concomitant infustion of low doss of rFVIIa and FEIBA in haemophilia patients with inhibitors","volume":"15","author":"Martinowitz","year":"2009","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.12.001_bb0535","first-page":"27","article-title":"Pharmacokinetics (PK), pharmacodynamics (PD), and PK.PD relationships of emicizumab in persons with haemophilia A (PwHA) with inhibitors from adolescent\/child (HAVEN 1) and paediatric (HAVEN 2) phase 3 studies","volume":"24","author":"Schmitt","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0540","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haemoatologica"},{"key":"10.1016\/bs.acc.2022.12.001_bb0545","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/hae.13689","article-title":"Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors","volume":"25","author":"Brophy","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0550","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors\u2014a single-center cohort","volume":"66","author":"Barg","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/bs.acc.2022.12.001_bb0555","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl. 3","key":"10.1016\/bs.acc.2022.12.001_bb0560","first-page":"1417","article-title":"New assays for monitoring haemophilia treatment","volume":"14","author":"Shima","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0565","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1055\/s-0037-1613023","article-title":"The utility of activated partial thromboplastin time (APTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C)","volume":"87","author":"Shima","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0570","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1538-7836.2006.01730.x","article-title":"The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay","volume":"4","author":"Matsumoto","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0575","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1111\/hae.13266","article-title":"Clot waveform analysis using CS-2000iTM distinguishes between very low and absent levels of factor VIII activity in patients with severe hemophilia A","volume":"23","author":"Matsumoto","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0580","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jth.12488","article-title":"Optimal monitoring of by-pass therapy in hemophilia A patients with inhibitor using clot waveform analysis","volume":"12","author":"Haku","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0585","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12185-021-03095-w","article-title":"Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis","volume":"113","author":"Mizumachi","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0590","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haemotologica"},{"key":"10.1016\/bs.acc.2022.12.001_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620719860025","article-title":"Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays","volume":"10","author":"Kizilocak","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0600","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29041","article-title":"Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors","volume":"68","author":"Lockhart","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/bs.acc.2022.12.001_bb0605","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0610","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment: A United Kingdom Haemophilia Centre Doctors\u2019 Organisation guideline","volume":"26","author":"Jenkins","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0615","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","article-title":"Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposal)","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0620","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/a-1127-6476","article-title":"Practical guideline of the GTH Haemophilia Board on the use of emicizumab in patients with haemophilia A","volume":"40","author":"Holstein","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/bs.acc.2022.12.001_bb0625","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/hae.14172","article-title":"Management of patient with severe haemophilia A withoug inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEUP, SIPMeL and SISET","volume":"26","author":"Coppola","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0630","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/hae.14010","article-title":"Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel","volume":"27","author":"Escuriola-Ettingshausen","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0635","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0640","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used for patients with acquired hemophilia A?","volume":"19","author":"Tiede","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2022.12.001_bb0645","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2022.12.001_bb0650","article-title":"The potential role of emicizumab prophylaxis in severe von Willebrand disease","volume":"87","author":"Barq","year":"2021","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/bs.acc.2022.12.001_bb0655","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16186","article-title":"How I manage severe von Willebrand disease","volume":"187","author":"Leebeek","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.acc.2022.12.001_bb0660","article-title":"Emicizumab for the treatment of acquired hemophilia a: a multicenter US case series, dfAbstract #496","author":"Poston","year":"2021"},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2022.12.001_bb0665","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-99-113623","article-title":"A novel, point-of-care, whole blood coagulation assay to monitor emicizumab therapy in patients with hemophilia","volume":"132","author":"Suster","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2022.12.001_bb0670","unstructured":"DMI website, n.d. http:\/\/www.dnamedinstitute.com\/press-releases\/2020\/rhealths-fviii-point-of-care-device-awarded-1-5m-direct-to-phase-ii-grant-from-the-nih\/, (Accessed May 28, 2022)."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242322001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T21:39:19Z","timestamp":1677533959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242322001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192869"],"references-count":133,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2022.12.001","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}